rs398123321

Variant summary

Our verdict is Likely pathogenic. The variant received 9 ACMG points: 9P and 0B. PP2PS3PS4_ModeratePM2

This summary comes from the ClinGen Evidence Repository: PTEN c.331T>C (p.Trp111Arg) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column).PS3: Phosphatase activity <50% of wild type (PMID 29785012, 29706350)PM2: Absent in large sequenced populations (PMID 27535533).PS4_M: Probands with phenotype specificity score of 2-3.5. (internal laboratory contributor(s) ClinVar Organization ID: 61756, ClinVar Organization ID: 19864)PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. LINK:https://erepo.genome.network/evrepo/ui/classification/CA000401/MONDO:0017623/003

Frequency

Genomes: not found (cov: 32)

Consequence

PTEN
NM_000314.8 missense

Scores

15
2
2

Clinical Significance

Likely pathogenic reviewed by expert panel P:6

Conservation

PhyloP100: 7.61

Publications

17 publications found
Variant links:
Genes affected
PTEN (HGNC:9588): (phosphatase and tensin homolog) This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded by this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The use of a non-canonical (CUG) upstream initiation site produces a longer isoform that initiates translation with a leucine, and is thought to be preferentially associated with the mitochondrial inner membrane. This longer isoform may help regulate energy metabolism in the mitochondria. A pseudogene of this gene is found on chromosome 9. Alternative splicing and the use of multiple translation start codons results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Feb 2015]
PTEN Gene-Disease associations (from GenCC):
  • Cowden syndrome 1
    Inheritance: AD Classification: DEFINITIVE, STRONG, MODERATE Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
  • PTEN hamartoma tumor syndrome
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • macrocephaly-autism syndrome
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Ambry Genetics, Genomics England PanelApp, Orphanet
  • renal cell carcinoma
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • leiomyosarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • activated PI3K-delta syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Bannayan-Riley-Ruvalcaba syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Cowden disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Lhermitte-Duclos disease
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Proteus-like syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • glioma susceptibility 2
    Inheritance: AD Classification: LIMITED Submitted by: Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_pathogenic. The variant received 9 ACMG points.

PS3
For more information check the summary or visit ClinGen Evidence Repository.
PS4
For more information check the summary or visit ClinGen Evidence Repository.
PM2
For more information check the summary or visit ClinGen Evidence Repository.
PP2
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PTENNM_000314.8 linkc.331T>C p.Trp111Arg missense_variant Exon 5 of 9 ENST00000371953.8 NP_000305.3
PTENNM_001304717.5 linkc.850T>C p.Trp284Arg missense_variant Exon 6 of 10 NP_001291646.4
PTENNM_001304718.2 linkc.-420T>C 5_prime_UTR_variant Exon 4 of 9 NP_001291647.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PTENENST00000371953.8 linkc.331T>C p.Trp111Arg missense_variant Exon 5 of 9 1 NM_000314.8 ENSP00000361021.3

Frequencies

GnomAD3 genomes
Cov.:
32
GnomAD4 exome
Cov.:
31
GnomAD4 genome
Cov.:
32

ClinVar

Significance: Likely pathogenic
Submissions summary: Pathogenic:6
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

PTEN hamartoma tumor syndrome Pathogenic:2
Jul 16, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces tryptophan, which is neutral and slightly polar, with arginine, which is basic and polar, at codon 111 of the PTEN protein (p.Trp111Arg). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with PTEN-related conditions (PMID: 1147684, 35102303; Invitae). ClinVar contains an entry for this variant (Variation ID: 92820). Advanced modeling performed at Invitae incorporating data from internal and/or published experimental studies (Invitae) indicates that this missense variant is expected to disrupt PTEN function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects PTEN function (PMID: 29706350, 29785012). For these reasons, this variant has been classified as Pathogenic. -

Jun 04, 2021
Clingen PTEN Variant Curation Expert Panel, Clingen
Significance:Likely pathogenic
Review Status:reviewed by expert panel
Collection Method:curation

PTEN c.331T>C (p.Trp111Arg) meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS3: Phosphatase activity <50% of wild type (PMID 29785012, 29706350) PM2: Absent in large sequenced populations (PMID 27535533). PS4_M: Probands with phenotype specificity score of 2-3.5. (internal laboratory contributor(s) ClinVar Organization ID: 61756, ClinVar Organization ID: 19864) PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. -

not provided Pathogenic:2
Jul 25, 2012
Eurofins Ntd Llc (ga)
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Sep 20, 2022
GeneDx
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Published functional studies demonstrate a damaging effect: significantly reduced phosphatase activity (Mighell et al., 2018); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with features overlapping Proteus syndrome and PTEN Hamartoma Tumor syndrome in published literature, and also observed in patients with a personal history consistent with pathogenic variants in this gene referred for genetic testing at GeneDx (Zhou et al., 2001); This variant is associated with the following publications: (PMID: 23757202, 16704655, 12938083, 12471211, 29785012, 29706350, 29416795, 11476841, 24475377) -

Cowden syndrome 1 Pathogenic:1
Jan 13, 2022
Molecular Diagnostics Laboratory, Catalan Institute of Oncology
Significance:Likely pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

PTEN c.331T>C variant meets criteria to be classified as likely pathogenic for PTEN Hamartoma Tumor syndrome (PHTS) with an autosomal dominant inheritance, following ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2 (https://www.clinicalgenome.org/affiliation/50012). Published functional assays have demonstrated that this variant significantly compromises the phosphatase activity of PTEN (PMID 29785012; 29706350) (PS3). This substitution is absent in large-scale general population reference sequencing datasets (PMID 32461654) (PM2). PTEN is defined by the PTEN Expert Panel as a gene with a low rate of benign missense variation, in which missense variants are a common mechanism of disease (PP2). In silico tools support that this missense variant has a deleterious effect (PP3). This variant was identified in a patient from our unit who met the consensus clinical diagnostic criteria for an operational diagnosis of Cowden syndrome (PMID 24136893; Rofes et al. 2022, submitted manuscript). The Cleveland Clinic (CC) score in this patient was >30 (PMID 21194675) (PS4_Supporting). In addition, this variant was previously reported in an individual diagnosed with Proteus syndrome, a genetic condition that also belongs to PHTS spectrum (PMID 11476841). -

Hereditary cancer-predisposing syndrome Pathogenic:1
Mar 31, 2025
Ambry Genetics
Significance:Pathogenic
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The p.W111R pathogenic mutation (also known as c.331T>C), located in coding exon 5 of the PTEN gene, results from a T to C substitution at nucleotide position 331. The tryptophan at codon 111 is replaced by arginine, an amino acid with dissimilar properties. This variant was identified in an individual who met clinical diagnostic criteria for PTEN hamartoma tumor syndrome (Ambry internal data). This variant was also identified in a patient with Proteus syndrome, but no details on clinical features were reported (Zhou X et al. Lancet, 2001 Jul;358:210-1). In a high-throughput assay measuring lipid phosphatase activity, this variant demonstrated deficient function (Mighell TL et al. Am. J. Hum. Genet., 2018 05;102:943-955). In another high-throughput assay measuring intracellular protein abundance, this variant demonstrated low protein abundance (Matreyek KA et al. Nat. Genet., 2018 06;50:874-882). Based on an internal structural analysis using published crystal structures, this variant is moderately destabilizing to the structure of the phosphatase catalytic domain of PTEN (Ambry internal data; Georgescu MM et al. Cancer Res., 2000 Dec;60:7033-8; Lee CU et al. Angew. Chem. Int. Ed. Engl., 2015 Nov;54:13796-800). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this variant is interpreted as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
1.0
BayesDel_addAF
Pathogenic
0.56
D
BayesDel_noAF
Pathogenic
0.57
CADD
Pathogenic
33
DANN
Uncertain
1.0
DEOGEN2
Pathogenic
0.96
D
Eigen
Pathogenic
0.77
Eigen_PC
Pathogenic
0.71
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Benign
0.74
T
M_CAP
Pathogenic
0.80
D
MetaRNN
Pathogenic
0.99
D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Pathogenic
3.9
H
PhyloP100
7.6
PrimateAI
Pathogenic
0.94
D
PROVEAN
Pathogenic
-12
D
REVEL
Pathogenic
0.96
Sift
Uncertain
0.012
D
Sift4G
Pathogenic
0.0
D
Polyphen
0.93
P
Vest4
0.96
MutPred
0.90
Gain of disorder (P = 0.003);
MVP
0.98
MPC
3.1
ClinPred
1.0
D
GERP RS
5.1
Varity_R
0.97
gMVP
0.99
Mutation Taster
=0/100
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs398123321; hg19: chr10-89692847; COSMIC: COSV64290246; API